Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Development of New Therapies to Drive Global Market

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Introduction

According to the report, the global ornithine transcarbamylase (OTC) deficiency treatment market was valued at ~US$ 600 Mn in 2019. It is projected to expand at a CAGR of ~4% from 2020 to 2030. Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by partial or complete lack of the enzyme ornithine transcarbamylase (OTC). OTC is one of six enzymes that play a role in the breakdown and removal of nitrogen in the body, a process known as urea cycle. Ammonia-scavenging drugs have been utilized in the treatment of urea cycle disorders. Benzoate and Glycerol/Sodium Phenyl Butyrate (NaPB) target liver-nitrogen metabolism by offering an alternative pathway for nitrogen disposal through the urinary excretion of hippurate and phenylacetylglutamine. A combination of a high biological value natural protein, an essential amino acid formula and a calorie supplement without protein and essential amino acids supplements may also be employed for the treatment of ornithine transcarbamylase deficiency.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78569

North America dominated the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019. It is expected to dominate the global market, in terms of revenue, during the forecast period.

Rise in Prevalence of Ornithine Transcarbamylase (OTC) Deficiency and Development of New Therapies to Drive Global Market

The surge in the number of patients with ornithine transcarbamylase (OTC) deficiency is likely fuel the global ornithine transcarbamylase (OTC) deficiency treatment market. The development of new therapies for ornithine transcarbamylase (OTC) deficiency treatment in the near future and favorable reimbursement policies for OTC deficiency treatment coupled with various patient assistance programs provided by several international and regional organizations are major factors driving the global ornithine transcarbamylase (OTC) deficiency treatment market.

For instance, in January 2020, The Assistance Fund (TAF), an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, announced the launch of a new financial assistance program for people living with urea cycle disorders. Formulation modification for better patient compliance is also a key factor driving the global ornithine transcarbamylase (OTC) deficiency treatment market.

Request for Analysis of COVID19 Impact on Ornithine Transcarbamylase (OTC) Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78569

Ravicti to Dominate Global Market

Based on product, the global ornithine transcarbamylase (OTC) deficiency treatment market has been segmented into Buphenyl, Ravicti, Ammonul, dietary supplements, and others. The Ravicti segment accounted for a major share of the global market in 2019 due to higher efficacy and cost of drug, and better patient compliance, which contributes toward higher revenues. The Buphenyl segment followed the Raviciti segment, in terms of share of the global market, in 2019, owing to pipeline products with improved patient compliance and lesser cost to patients.

Oral a Preferred Route of Administration

In terms of route of administration, the global ornithine transcarbamylase (OTC) deficiency treatment market has been bifurcated into oral and intravenous. The oral segment dominated the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019. It is expected to maintain its dominant share by 2030. Oral is also a highly lucrative segment. It is projected to expand at a notable CAGR during the forecast period, owing to patient preference for oral route and convenience offered by the oral route, approval & launch of oral medication, availability of a large number of products that can be administered through oral route, and new products with improvement in formulation modification for taste masking.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78569

Hospital Pharmacies to be Key Distribution Channel

In terms of distribution channel, the global ornithine transcarbamylase (OTC) deficiency treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for a major share of the market in 2019 due to higher number of prescriptions filled at these hospital pharmacies, favorable reimbursement scenario, strong supply chain management, and various patient assistance programs run by pharmaceutical companies.

North America to Dominate Global Market

In terms of region, the global ornithine transcarbamylase (OTC) deficiency treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019, owing to a rise in the total number of reported cases of ornithine transcarbamylase (OTC) deficiency, favorable reimbursement policies, presence of major companies, various clinical studies in the region for urea cycle disorder, and better screening approaches for rare diseases. For instance, according to the U.S. National Library of Medicine, prevalence of ornithine transcarbamylase deficiency have ranged from 1 in 14,000 to 1 in 77,000 people in the U.S. The market in Asia Pacific is projected to expand at a higher CAGR during the forecast period, owing to increase in awareness about ornithine transcarbamylase (OTC) deficiency and other urea cycle disorders, surge in screening of patients for the diagnosis of ornithine transcarbamylase (OTC) deficiency, increase in distribution tie-ups between major companies, and rise in investments by major companies in the region.

Buy Ornithine Transcarbamylase (OTC) Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=78569&ltype=S

Competition Landscape

The global ornithine transcarbamylase (OTC) deficiency treatment market is fragmented in terms of the number of players, with entry of several new players. Key players in the global market include Abbott, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics plc, Nestlé, Bausch Health Companies, Inc., Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics, Inc., and Acer Therapeutics. Mergers, acquisitions & strategic collaborations, distribution tie-ups, increased research & development expenditure, and new product launches are major strategies adopted by companies in the global ornithine transcarbamylase (OTC) deficiency treatment market.

Browse More Trending Reports by Transparency Market Research:

Metastatic Melanoma Market: https://www.transparencymarketresearch.com/metastatic-melanoma-market.html

Mycobacterium Infections Treatment Market: https://www.transparencymarketresearch.com/mycobacterium-infections-treatment-market.html

Pancreatic Fistula Market: https://www.transparencymarketresearch.com/pancreatic-fistula-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit Bhisey
Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Back to news